BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
火曜日, 9 29

Pacific Biosciences of California Inc

PACBNASDAQ
Trade with Public
Trade with Public
$1.71
0.095.56%
近くで: Sep 28, 5:00 PM EST
$1.69
-0.02-1.17%
時間外: 7:36 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Pacific Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacific Biosciences (PACB).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

6Buy
5Hold
1Sell
Consensus RatingNeutral# Analysts12Avg. Consensus PT$2Upside to Avg. PT+36.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026UBSDoug SchenkelAssumesNeutral$2→$1
May 11, 2026BarclaysLuke SergottPT RaiseUnderweight$1→$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
Benzinga Newsdesk

PRO
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.
Benzinga Newsdesk

PRO
Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.
Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overweight and raises the price target from $1.8 to $2.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved